Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Laurence Klotz CM, MD, FRCSC

Laurence Klotz CM, MD, FRCSC

Professor of Surgery, University of Toronto, Toronto, Ontario, Canada

Laurence Klotz, MD, is the past Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He is also Chairman of the World Uro-Oncology Federation and a past president of the Urological Research Society and the Canadian Urological Association. Dr. Klotz was the Founding Editor-in-Chief of  both the Canadian Journal of Urology and the Canadian Urology Association Journal, and is now Editor Emeritus of the CUAJ. He was the founder and is chairman of the Canadian Urology Research Consortium.

Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. Dr. Klotz continued his postgraduate studies with a special fellowship at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology and tumour biology.

Dr. Klotz is a widely published uro-oncologist with over 300 publications and 4 books. His main research interest has been prostate cancer. He serves on the boards of  many medical/scientific organizations and  journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases,  Brazilian Journal of Urology,  Italian Journal of Urology, and World Journal of Urology. He was recently awarded the Queen’s Jubilee Medal for meritorious public service.

Recent Contributions to PracticeUpdate:

  1. Patients With Intermediate-Risk Prostate Cancer May Be Good Candidates for Active Surveillance: Con
  2. Intermediate-Term Outcomes for Men With Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance
  3. MRI and Transrectal Ultrasound–Guided Fusion Biopsy to Detect Progression in Patients With Prostate Cancer
  4. Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening
  5. Baseline PSA Levels in Midlife Predict Lethal Prostate Cancer
  6. Diffusion-Weighted MRI in Active Surveillance for Prostate Cancer
  7. Omission of Confirmatory Biopsy for Prostate Cancer in Patients on Active Surveillance
  8. Treatment Differences and Outcomes of ERSPC Rotterdam
  9. Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer
  10. Prostate Cancer Surveillance Appears Safe Through 15 Years

Recently Updated